17 citations
,
February 2011 in “Expert Opinion on Drug Safety” This review discusses adverse effects associated with pegylated IFN therapy for chronic hepatitis C and highlights the potential of new antiviral drugs to reduce side effects and improve treatment adherence, but reports no new clinical results.
June 2016 in “Afro-Egyptian Journal of Infectious and Endemic Diseases” In this study, 97% of patients undergoing pegylated interferon alfa2a and ribavirin therapy for chronic hepatitis C experienced one or more skin-related side effects, with hair loss being the most common.
August 2026 in “Clinical Cosmetic and Investigational Dermatology” In this study, pegylated interferon alpha therapy was independently associated with more severe hair loss, particularly acute telogen effluvium, in chronic hepatitis B patients with alopecia, compared to nucleos(t)ide analog therapy, emphasizing the importance of monitoring and counseling, especially for younger female patients.
32 citations
,
October 2004 in “Pharmacotherapy” In this study, peginterferon alfa-2b plus ribavirin therapy in hepatitis C patients was associated with serious adverse drug reactions in 20% of cases, highlighting differences from clinical trial findings.
January 2014 in “대한피부과학회지” This case study in a hepatitis B patient observed that pegylated interferon alpha2a treatment may induce localized alopecia areata, which appeared to correlate with treatment administration and discontinuation.
